News | August 11, 2024
Aurobindo posts Q1 FY25 PAT higher by 61% at Rs. 7,567 Cr
Revenue from Operations increased by 10.5% YoY to Rs. 7,567 crore with growth across the businesses
Revenue from Operations increased by 10.5% YoY to Rs. 7,567 crore with growth across the businesses
The company has seamlessly integrated the business acquired from Yash Pharma into Jagsonpal and are now confident of aligning the margins of the acquired business with that of Jagsonpal ahead of schedule
The pharma market is showing encouraging signs of improvement, positioning us well for future growth
Expect the international business including CDMO business to pick-up in the second half of the financial year
Organization to provide vaccinations & treatments for several monsoon related diseases and illnesses across all 102 clinics
Pharmaceuticals and Consumer Health report higher sales (Fx & portfolio adj.) and lower earnings
The drugmaker's net profit slipped 26 per cent on-year to Rs 143.8 crore
Both departments will be equipped with specialized professionals and state-of-the-art facilities ensuring the highest standards of care
The acquisition of LumiraDx’s Point of Care technology received all required antitrust and regulatory clearances
The revenue for the Q1FY25 came in at Rs 1,085.7 crore, up 16.6 per cent YoY
Subscribe To Our Newsletter & Stay Updated
